| Name | Title | Contact Details |
|---|---|---|
Sean Clayton |
Executive Vice President and General Counsel | Profile |
Melanie Gloria |
Group VP Development Operations - ClinOps, Compliance and Standards, Regulatory, Safety and PV | Profile |
David Styler |
SVP, Chief Compliance Officer | Profile |
Blue Mountain Quality Resources Inc is a State College, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Built on a foundation of professional expertise and personal service, Shoppers Drug Mart has been meeting Canadians` health care needs for 50 years. What was once a small pharmacy in Toronto has grown into an organization of over 1,200 stores from coast to coast, becoming an indelible part of the lives of Canadians, young and old. Yet despite our growth, we have never forgotten our origins. We have always remained true to our belief that the personal satisfaction of each and every customer is at the root of our success - and it can only be ensured by the commitment of people who realize that success is built one customer at a time.
Robert E Mason Co is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UI Magic Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.